Cosmo Pharmaceuticals Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Giovanni Di Napoli
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | less than a year |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | less than a year |
Actualizaciones recientes de la dirección
Recent updates
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
Nov 22
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
May 02Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 28Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Mar 26Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Dec 01Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 29We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Nov 24Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Mar 31These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well
Aug 02Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)
May 20Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly
Apr 03When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?
Mar 07CEO
Giovanni Di Napoli (50 yo)
less than a year
Permanencia
Mr. Giovanni Di Napoli is Chief Executive Officer and Director of Cosmo Pharmaceuticals N.V. from May 24, 2024. He was President of Gastrointestinal at Medtronic plc. He is an accomplished leader with an e...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 18.8yrs | €1.16m | sin datos | |
| Executive VP of Corporate Governance | no data | sin datos | sin datos | |
| Chief Executive Officer & Director | less than a year | sin datos | sin datos | |
| Founder & Non-Executive Director | 18.8yrs | €400.00k | sin datos | |
| Chief Financial Officer | no data | sin datos | sin datos | |
| Chief Operating Officer | 3.8yrs | sin datos | sin datos | |
| Qualified Person & Technical Director | 13.2yrs | sin datos | sin datos | |
| Chief Scientific Officer | 2.6yrs | sin datos | sin datos | |
| Head of Investor Relations | 2.8yrs | sin datos | sin datos | |
| Chief People Officer | 3.8yrs | sin datos | sin datos | |
| Chief Manufacturing Officer | 27.8yrs | sin datos | sin datos | |
| President of Cosmo Intelligent Medical Devices | no data | sin datos | sin datos |
2.8yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de COPN se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 18.8yrs | €1.16m | sin datos | |
| Executive VP of Corporate Governance | less than a year | sin datos | sin datos | |
| Chief Executive Officer & Director | less than a year | sin datos | sin datos | |
| Founder & Non-Executive Director | 18.8yrs | €400.00k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Non-Executive Director | 12.6yrs | €128.79k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Non-Executive Director | less than a year | sin datos | sin datos | |
| Non-Executive Director | less than a year | sin datos | sin datos |
0.5yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de COPN no se considera experimentada (0.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.